PTC Therapeutics, Inc. (PTCT) today announced that the FDA has accepted the New Drug Application for Vatiquinone, a proposed treatment for Friedreich's ataxia, and granted Priority Review.
The U.S. regulatory agency has set the target action date for August 19, 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com